CNR1 and atherosclerosis: The overall goal of this work was to establish endothelial CB1 as a mechanosensitive regulator of atherosclerosis and to develop isoflavone-derived CB1 antagonists as potential oral therapeutics for disturbed flow-induced endothelial dysfunction.